Ensign Peak Advisors Inc Has $8.36 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

Ensign Peak Advisors Inc boosted its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 67.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 308,241 shares of the company's stock after purchasing an additional 124,456 shares during the period. Ensign Peak Advisors Inc owned about 0.54% of Structure Therapeutics worth $8,359,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Barclays PLC lifted its holdings in Structure Therapeutics by 64.5% during the 3rd quarter. Barclays PLC now owns 81,138 shares of the company's stock valued at $3,562,000 after purchasing an additional 31,815 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of Structure Therapeutics by 230.0% during the 3rd quarter. Principal Financial Group Inc. now owns 545,359 shares of the company's stock worth $23,936,000 after buying an additional 380,115 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Structure Therapeutics by 302.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company's stock worth $1,489,000 after buying an additional 25,500 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after buying an additional 1,122 shares during the period. Finally, FNY Investment Advisers LLC acquired a new position in Structure Therapeutics in the 4th quarter valued at about $40,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Stock Down 3.7%

GPCR opened at $24.62 on Tuesday. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -33.27 and a beta of -1.69. Structure Therapeutics Inc. has a twelve month low of $13.22 and a twelve month high of $62.74. The company has a 50-day simple moving average of $20.98 and a 200 day simple moving average of $26.77.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). Sell-side analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on GPCR. William Blair began coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating for the company. Citigroup began coverage on Structure Therapeutics in a report on Friday, May 2nd. They set a "buy" rating and a $60.00 price target for the company. Finally, HC Wainwright decreased their price objective on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Monday. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $78.00.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.